ResearcherYamagata UniversityActive in the last 2 years
Atsushi Satō
Matched on OpenAlex author ID A5104134720. Sources: OpenAlex.
Their work
- Papers
- 10
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 55
2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper
Papers 10
- Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: stu… Co-author DOI 10.1186/s12885-024-11973-9↗
- Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan… Co-author DOI 10.1136/bmjopen-2021-048833↗
- Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro a… Co-author DOI 10.3390/cancers14133162↗
- nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
- Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis. Co-author DOI 10.1074/jbc.ra120.015223↗
- [A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery]. Co-author PMID 32156995↗
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
- JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Co-author DOI 10.18632/oncotarget.2693↗
- [Second-line chemotherapy for advanced pancreatic cancer]. Co-author PMID 25963687↗
- Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
Closest collaborators
The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kenji Amagai · 1 shared paper, 2024 · strength 0.21
- Hiroo Imai · 1 shared paper, 2024 · strength 0.21
- Chikashi Ishioka · 1 shared paper, 2024 · strength 0.21
- Hiroyuki Shibata · 1 shared paper, 2024 · strength 0.21
- Yoshito Komatsu · 2 shared papers, 2020–2022 · strength 0.21
- Paper Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination c… DOI 10.1136/bmjopen-2021-048833↗
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Hiroaki Taniguchi · 1 shared paper, 2022 · strength 0.19
- Jiaxuan Song · 1 shared paper, 2022 · strength 0.19
- Kumiko Ui‐Tei · 1 shared paper, 2022 · strength 0.19
- Takenori Takahata · 2 shared papers, 2015–2019 · strength 0.17
- Tatsuya Ioka · 3 shared papers, 2013–2020 · strength 0.17
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Paper Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone… DOI 10.1136/esmoopen-2016-000151↗
- Paper Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗
- Junji Furuse · 3 shared papers, 2013–2020 · strength 0.17
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Paper Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone… DOI 10.1136/esmoopen-2016-000151↗
- Paper Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗
- Takuji Okusaka · 3 shared papers, 2013–2020 · strength 0.17
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Paper Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone… DOI 10.1136/esmoopen-2016-000151↗
- Paper Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗
- Chifumi Kitanaka · 2 shared papers, 2015–2020 · strength 0.17
- Shuhei Suzuki · 2 shared papers, 2015–2020 · strength 0.17
- Masahiro Yamamoto · 1 shared paper, 2020 · strength 0.12
- Tomomi Sanomachi · 1 shared paper, 2020 · strength 0.12
- Masafumi Ikeda · 2 shared papers, 2013–2020 · strength 0.12
- Paper nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese p… DOI 10.1002/cam4.3558↗
- Paper Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced a… DOI 10.1200/jco.2012.43.3680↗
- Yuh Sakata · 1 shared paper, 2022 · strength 0.12
- Kazuaki Harada · 1 shared paper, 2022 · strength 0.12
- Shintaro Nakano · 1 shared paper, 2022 · strength 0.12
- Yasuyuki Kawamoto · 1 shared paper, 2022 · strength 0.12
- Naoya Sakamoto · 1 shared paper, 2022 · strength 0.12
- Shinya Kajiura · 1 shared paper, 2022 · strength 0.12
- Shoji Nakamori · 1 shared paper, 2020 · strength 0.09
- Ken Kawabe · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.